Cellectis Touts Positive Preliminary Data From Two Leukemia Trials

• Cellectis S.A (NASDAQ: CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01 trial (evaluating UCART123).

• Compared to the last clinical update on BALLI-01 at ASH 2021, the presented data comes from five additional patients who received UCART22 at dose level 3 (DL3) 5x106 cells/kg after lymphodepletion with FCA.

• Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients.

• A patient experienced a durable, minimal residual disease (MRD) negative complete response with incomplete count recovery (CRi) that continues beyond six months.

• The company also shared preliminary data from patients who received UCART123.

• The FCA LD regimen resulted in robust lymphodepletion for greater than 28 days in all patients. Seven out of nine patients demonstrated UCART123 expansion.

• Two out of eight patients (25%) at DL2 with the FCA arm achieved a meaningful response.

• A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.

• Price Action: CLLS shares are up 8.52% at $2.42 on the last check Tuesday.

• Photo Via Company

See more from Benzinga

• Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication

• Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B

• Donald Trump's Wife Melania Was Convinced He Was 'Screwing Up,' Best-Selling Book Reveals

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.